GenomeDx Adds Multiple Leading Cancer Centers to Its Proprietary Genomics Resource Information Database Platform (Decipher GRID)

SAN DIEGO, Sept. 13, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that it has expanded access to its Decipher Genomics Resource Information Database (Decipher GRID^®) to a new group of leading cancer centers, allowing them to join the existing Decipher GRID network. The new group of centers includes the Glickman Urological and Kidney Institute at Cleveland Clinic, Tulane Cancer Center, Chesapeake Urology, University of Michigan Cancer Center, University of Maryland Medical Center and Rush University Medical Center. Decipher GRID is a cloud-based genomic expression database that provides participating partners with access to genomic information of patients diagnosed with and treated for urological cancer.

"Accessing Decipher GRID will give us the ability to obtain expansive genomic information and share new insights, allowing us to enhance our application of genomics to the management of our patients with urologic cancers," said Eric Klein, M.D., chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic. "We look forward to being actively involved in advancing the use of genomic information to deliver better care for our patients."

"Having access to this database will help us to compare genomic data among patients and will help researchers and clinicians share insights, data and research opportunities that ultimately will benefit our patients during their fight against cancer," said Leslie Deane, M.D., associate professor of urology at Rush University Medical Center in Chicago.

"GenomeDx has built a tremendous genomic repository in GRID, and expanding our collaborative efforts with these leading cancer centers will allow us to marry the power of genomic information with prospective clinical outcomes for patients," said Doug Dolginow, M.D., chief executive officer of GenomeDx Biosciences. "We believe as the data sharing capabilities and collaboration enabled by Decipher GRID are increasingly embraced by leading cancer centers and others within the urology and oncology communities, Decipher GRID will facilitate insights on a new scale and help drive important discoveries about urologic cancers."

Decipher GRID has been the foundation of more than 45 clinical studies relating to GenomeDx's Decipher® Prostate Cancer Classifier products, published in collaboration with researchers from more than 55 cancer centers in the United States. GenomeDx believes the collaborative benefits and contributions provided by these cancer centers and other contributors to Decipher GRID can accelerate genomic discoveries within the urologic cancer community and help translate genomic solutions into clinical applications at a rapid pace.

About Decipher® Prostate Cancer Classifier Tests
Our Decipher Prostate Cancer Classifier tests currently include Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men with localized prostate cancer after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.

About Decipher GRID®
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic expression database that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patient tumors, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables us to more rapidly discover, develop, commercialize and drive the adoption of our existing and new genomic tests. Through Decipher GRID, GenomeDx is building a suite of genomic tests in urologic cancer that we believe will allow us to achieve our goals of reducing costs to the healthcare system and improving patient lives, from screening through late-stage therapy.    

About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California.

Learn more at www.GenomeDx.com

SOURCE GenomeDx Biosciences

Related Links

https://www.genomedx.com